Improved glycaemic control without increased risk of hypoglycaemia with a 25% insulin/lispro 75% npl mixture twice daily compared with NPH twice daily in patients with type 2 diabetes

Journal of Applied Therapeutic Research

Volumn 4, Issue 4, 2004, Pages 3-9

  Reviriego, J ^a   Herz, M ^b   Roach, P ^c  

^a ELI LILLY AND COMPANY   (Spain)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Glycaemic control; Humalog Mix25; Insulin lispro; Type 2 diabetes

Indexed keywords

EID: 14844362478     PISSN: 10292659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Anderson, J. H. Jr., Brunelle, R. L. et al. (1997). Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulindependent diabetes mellitus. Archives of Internal Medicine, 157, 1249-1255.
2. Bell, D. S., Clements, R. S. Jr. et al. (1991). Dosage accuracy of self-mixed versus premixed insulin. Archives of Internal Medicine, 151, 2265-2269.
3. Bergenstal, R. M. (2000). Optimization of insulin therapy in patients with type 2 diabetes. Endocrine Practice, 6, 93-97.
4. Bonora, E. (2002). Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. International Journal of Clinical Practice, (Suppl 129) 5-11.
5. Ceriello, A., Motz, E. et al. (1997). Hyperglycemia counterbalances the anti-hypertensive effect of glutathione in diabetic patients: evidence linking hypertension and glycemia through the oxidative stress in diabetes mellitus. Journal of Diabetes Complications, 11, 250-255.
6. Coscelli, C., Calabrese, G. et al. (1992). Use of a premixed insulin among the elderly: reduction of errors in patient preparation of mixtures. Diabetes Care, 15, 1628-1630.
7. ™). Disease Management, 9, 711-730.
8. De Cosmo, S., Earle, K. et al. (1993). Glucose-induced changes in renal haemodynamics in proteinuric type 1 (insulindependent) diabetic patients. Diabetologia, 36, 622-627.
9. De Vegt, F., Dekker, J. M. et al. (1999). Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia, 42, 926-931.
10. European Diabetes Policy Group (1999). A desktop guide to type 2 diabetes mellitus. Diabetic Medicine, 16, 716-730.
11. Giugliano, D., Marfella, R. et al. (1997). Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation, 95, 1783-1790.
12. Hanefeld, M. (2002). Postprandial hyperglycaemia: noxious effects on the vessel wall. International Journal of Clinical Practice, (Suppl 129), 45-50.
13. Koivisto, V. A. (1993). Insulin therapy in type II diabetes. Diabetes Care, 16, (Suppl. 3) 29-39.
14. Koivisto, V. A., Tuominen, J. A. et al. (1999). Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care, 22, 459-462.
15. Lindström, T. H., Arnqvist, H. J. et al. (1992). Effect of conventional and intensified insulin therapy on free-insulin profiles and glycemic control in NIDDM. Diabetes Care, 15, 27-34.
16. Malone, J. K., Yang, H. et al. (2000). Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. Diabetes Metabolism, 26, 481-487.
17. Marfella, R., Esposito, K. et al. (2000). Circulation adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation, 101, 2247-2251.
18. Pirags, V., Assert, R. et al. (1996). Activation of human platelet protein kinase C-beta 2 in vivo in response to acute hyperglycemia. Experimental Clinical Endocrinology in Diabetes, 104, 431-440.
19. Roach, P., Trautman, M. et al. (1999). Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50. Clinical Therapeutics, 21, 523-534.
20. Roach, P., Yue, L. et al. (1999). Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care, 22, 1258-1261.
21. Schmetterer, L., Woltz, M. (1999). Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia, 42, 387-405.
22. Shaw, J. E., Hidge, A. M. et al. (1999). Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia, 42, 1050-1054.
23. Sievers, M. L., Bennet, P. et al. (1999). Effect of glycemia on mortality in Pima Indians with type 2 diabetes. Diabetes, 48, 896-902.
24. The DECODE study group on behalf of the European Diabetes Epidemiology Group (2001). Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Archives of Internal Medicine, 161, 397-404.
25. Turner, H. E., Matthews, D. R. (2000). The use of fixed-mixture insulins in clinical practice. European Journal of Clinical Pharmacology, 56, 19-25.
26. World Health Organization: Prevention of Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Organization, 1994 (Tech. Rep. Ser., No. 844).
27. Williams, S. B., Goldfine, A. B. et al. (2000). Acute hyperglycemia attenuates endothelium-dependent vasodilatation in humans in vivo. Circulation, 97, 1695-1701.
28. Yeap, B. B., Russo, A. et al. (1996). Hyperglycemia affects cardiovascular autonomic nerve function in normal subjects. Diabetes Care, 19, 880-882.
29. Yki-Jarvinen, H. (2000). Comparison of insulin regimens for patients with type 2 diabetes. Current Opinion in Endocrinology and Diabetes, 7, 175-183. (Pubitemid 30461229)